Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. PBM
PBM logo

PBM Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.985
Open
5.900
VWAP
5.66
Vol
131.90K
Mkt Cap
6.41M
Low
5.405
Amount
746.55K
EV/EBITDA(TTM)
--
Total Shares
1.15M
EV
5.69M
EV/OCF(TTM)
--
P/S(TTM)
--
Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
Show More

Events Timeline

(ET)
2026-04-20
16:30:00
Major Averages Decline Amid Escalating Tensions with Iran
select
2026-04-20
12:00:00
Major Averages Decline Amid Rising Tensions with Iran
select
2026-04-20
08:10:00
Psyence Biomedical Updates Strategic Position in Global Ibogaine Market
select
2026-04-17 (ET)
2026-04-17
15:10:00
Psyence Biomedical Ltd Trading Halted Due to Volatility Trading Pause
select
2026-04-17
10:00:00
Trump Administration to Examine Ibogaine Drug Safety
select
2026-04-17
09:30:00
Psyence Biomedical Welcomes U.S. Evaluation of Ibogaine Safety
select
2026-04-16 (ET)
2026-04-16
12:10:00
White House Considers Safety Review of Ibogaine
select
link

News

Yahoo Finance
8.5
05-05Yahoo Finance
Pacific Bay Minerals Adopts Semi-Annual Reporting
  • Reporting Frequency Change: Pacific Bay Minerals is shifting to semi-annual financial reporting starting with Q1 2026, complying with the British Columbia Securities Commission's Order 51-933, aimed at reducing management costs while enhancing transparency.
  • Exploration Project Reactivation: This move allows the company to focus more resources on reactivating the Haskin-Reed critical minerals project, which is expected to drive future mineral development and potential revenue.
  • Significant Project Potential: The Haskin-Reed project, located in the Cassiar Region, hosts rich deposits of tungsten, copper, bismuth, silver, lead, and zinc across over 150 drill holes, indicating substantial exploration potential.
  • Acquisition Agreement Signed: The company recently signed an option agreement to acquire the Mount Haskins claims, directly enhancing its resource base in the area, which is anticipated to support future mining activities.
Newsfilter
8.5
04-21Newsfilter
Trump Signs Order to Accelerate Psychedelic Drug Research
  • Policy Driving Research: President Trump signed an executive order directing health regulators to expedite reviews of psychedelic drugs and increase federal funding, responding to advocates like Joe Rogan, indicating a governmental acknowledgment of the potential medical uses of psychedelics.
  • Clinical Trial Progress: Current trials show strong evidence for the use of psychedelics in treating severe depression and PTSD, particularly in patients unresponsive to existing treatments, suggesting these drugs could become viable new therapeutic options.
  • Drug Authorization Status: In the U.S., Johnson & Johnson's esketamine nasal spray is approved for treatment-resistant depression, while countries like Australia and Switzerland have authorized psilocybin and MDMA for various uses, reflecting a global recognition of the therapeutic potential of psychedelics.
  • Risk Assessment: Despite the therapeutic promise of psychedelics, risks such as acute anxiety and confusion during administration, as well as higher risks when used outside clinical settings, highlight the need for caution in their research and application.
stocktwits
8.5
04-21stocktwits
Trump Signs Executive Order to Accelerate Psychedelic Research
  • Policy Catalyst: Trump's executive order directs the FDA to expedite the review of psychedelic drugs and commits $50 million to related clinical research, which is expected to significantly enhance market recognition and attract investment in psychedelic therapies.
  • Inventory Advantage: Psyence Biomedical currently holds standardized, stabilized GMP-compliant ibogaine doses, addressing the scarcity of clinical-grade materials in the market, which is likely to strengthen its competitive position in the psychedelic drug sector.
  • Vertical Integration: Through its investment in PsyLabs, Psyence has established a vertically integrated platform that spans sourcing in Africa, extraction, purification, and pharmaceutical production, effectively reducing supply chain delays and accelerating progress in ibogaine-based clinical research.
  • Surging Market Sentiment: PBM shares surged 182% over the past three days, with retail sentiment on Stocktwits being extremely bullish, indicating strong market confidence in the company's future, which may attract more investors to the psychedelic drug market.
stocktwits
8.5
04-20stocktwits
AtaiBeckley Price Target Raised to $15 Amid Positive Drug Trial News
  • Price Target Increase: Canaccord analyst Sumant Kulkarni raised AtaiBeckley's price target from $14 to $15 while maintaining a 'Buy' rating, indicating strong confidence in the company's future performance.
  • Clinical Trial Progress: Atai is preparing for its investigational psychedelic drug BPL-003 to enter late-stage trials this quarter, which is designed for treatment-resistant depression and is expected to significantly enhance the company's market position in this sector.
  • Positive Market Reaction: Following President Trump's executive order to expedite psychedelic drug research, AtaiBeckley shares surged 28% on Monday, potentially marking the best single-day gain, reflecting growing optimism in the psychedelic drug industry.
  • Analyst Consensus: According to Koyfin data, all 14 analysts covering ATAI rate it 'Buy' or higher, with a 12-month average price target of $13.83, representing a potential upside of about 166% from current trading levels.
stocktwits
8.5
04-20stocktwits
Trump Accelerates Psychedelic Research, PBM Stock Soars
  • Policy-Driven Funding: Trump signed an executive order directing the FDA to expedite reviews of psychedelic medicines while committing $50 million for clinical research, providing robust policy support for the legalization and application of psychedelics.
  • Stock Surge Performance: Following Trump's announcement, Psyence Biomedical (PBM) shares surged over 111% in premarket trading on Monday and achieved a remarkable 185% increase last week, indicating strong market performance and renewed investor confidence in the psychedelic sector.
  • Production Capacity Enhancement: Psyence has established a GMP-compliant platform for producing medical-grade ibogaine, ensuring its application in clinical research and drug development, and has sourced high-purity ibogaine hydrochloride from Africa, showcasing its competitive edge in the global market.
  • Market Sentiment Extremely Bullish: Retail sentiment for PBM on Stocktwits has remained extremely bullish, with message volumes surging 15,100% over the past month, reflecting strong market expectations and confidence in PBM's future, particularly regarding the potential demand for psychedelic therapies.
stocktwits
4.5
04-20stocktwits
U.S. Stock Futures Retreat Amid Renewed Geopolitical Tensions
  • Futures Pullback: U.S. stock futures retreated early Monday after last week's record highs, with S&P 500 and Nasdaq futures down 0.6% and 0.7% respectively, indicating rising investor concerns over geopolitical risks.
  • Strait of Hormuz Tensions: Iran's announcement to keep the critical shipping route restricted, coupled with President Trump's confirmation of seizing an Iranian cargo ship, has reignited market focus on oil price volatility, prompting renewed interest in oil-linked stocks like BATL and EONR.
  • Psychedelic Stocks Surge: Following President Trump's executive order to expedite psychedelic drug approvals, stocks like Psyence Biomedical (PBM), Definium Therapeutics (DFTX), and Compass Pathways (CMPS) are gaining retail investor attention, reflecting a growing market interest in mental health treatments.
  • Tesla's Positive Outlook: Tesla is on track for its first positive month this year, with Elon Musk downplaying competitive fears from China's BYD, emphasizing that execution, rather than competition, is the key challenge for the EV maker, showcasing the company's confidence in its future performance.

Valuation Metrics

The current forward P/E ratio for Psyence Biomedical Ltd (PBM.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Psyence Biomedical Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top moving penny stocks
Intellectia · 735 candidates
Market Cap: <= 5.00BPrice: $0.00 - $10.00Volume: >= 50,000Price Change Pct: >= $2.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
6.73M
YXT logo
YXT
YXT.Com Group Holding Ltd
22.01M
UCAR logo
UCAR
U Power Ltd
2.90M
BZAI logo
BZAI
Blaize Holdings Inc
212.35M
LZM logo
LZM
Lifezone Metals Ltd
349.64M
FGI logo
FGI
FGI Industries Ltd
9.33M
list all stock up 5% premarket
Intellectia · 156 candidates
Pre Market Price Change: >= $5.00
Ticker
Name
Market Cap$
top bottom
EFOI logo
EFOI
Energy Focus Inc
13.18M
PBM logo
PBM
Psyence Biomedical Ltd
6.73M
YXT logo
YXT
YXT.Com Group Holding Ltd
22.01M
ISPC logo
ISPC
iSpecimen Inc
3.46M
LZM logo
LZM
Lifezone Metals Ltd
349.64M
WSHP logo
WSHP
WeShop Holdings Ltd
334.42M
stocks under $1 that fell 5% or more
Intellectia · 66 candidates
Price: <= $1.00Price Change Pct: <= $-5.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
JFBR logo
JFBR
Jeffs Brands Ltd
2.33M
SLE logo
SLE
Super League Enterprise Inc
5.88M
PN logo
PN
Skycorp Solar Group Ltd
11.55M
stocks under $2 that fell 5% or more
Intellectia · 109 candidates
Price: <= $2.00Price Change Pct: <= $-5.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
VERO logo
VERO
Venus Concept Inc
3.51M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
JFBR logo
JFBR
Jeffs Brands Ltd
2.33M
SURG logo
SURG
Surgepays Inc
25.72M
find stocks under $2 that fell 5% or more
Intellectia · 109 candidates
Price: <= $2.00Price Change Pct: <= $-5.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
VERO logo
VERO
Venus Concept Inc
3.51M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
JFBR logo
JFBR
Jeffs Brands Ltd
2.33M
SURG logo
SURG
Surgepays Inc
25.72M
stocks with an rsi under 5
Intellectia · 221 candidates
Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
SURG logo
SURG
Surgepays Inc
25.72M
FEDU logo
FEDU
Four Seasons Education (Cayman) Inc
17.36M
JL logo
JL
J-Long Group Ltd
13.50M
with an rsi under 10
Intellectia · 221 candidates
Rsi Category: oversold
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
SURG logo
SURG
Surgepays Inc
25.72M
FEDU logo
FEDU
Four Seasons Education (Cayman) Inc
17.36M
JL logo
JL
J-Long Group Ltd
13.50M
stocks that fell over 20% yesterday
Intellectia · 19 candidates
Price Change Pct: $-100.00 - $-20.00
Ticker
Name
Market Cap$
top bottom
PBM logo
PBM
Psyence Biomedical Ltd
890.11K
IOBT logo
IOBT
IO Biotech Inc
14.94M
VERO logo
VERO
Venus Concept Inc
3.51M
IBG logo
IBG
Innovation Beverage Group Ltd
3.33M
JFBR logo
JFBR
Jeffs Brands Ltd
2.33M
SURG logo
SURG
Surgepays Inc
25.72M
stock to buy low and sell high today
Intellectia · 10 candidates
Relative Vol: >= 2Pe Ttm: <= 15Rsi 14: <= 25Moving Average Relationship: PriceBelowMA20Week Price Change Pct: <= $-3.00
Ticker
Name
Market Cap$
top bottom
DGNX logo
DGNX
Diginex Ltd
292.33M
NLOP logo
NLOP
Net Lease Office Properties
279.84M
IH logo
IH
iHuman Inc
92.42M
IOBT logo
IOBT
IO Biotech Inc
14.94M
JL logo
JL
J-Long Group Ltd
13.50M
FTFT logo
FTFT
Future Fintech Group Inc
10.55M

Whales Holding PBM

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Psyence Biomedical Ltd (PBM) stock price today?

The current price of PBM is 5.5900002 USD — it has decreased -7.14

What is Psyence Biomedical Ltd (PBM)'s business?

Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The Company is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. It is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.

What is the price predicton of PBM Stock?

Wall Street analysts forecast PBM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Psyence Biomedical Ltd (PBM)'s revenue for the last quarter?

Psyence Biomedical Ltd revenue for the last quarter amounts to -1.51M USD, increased 30.18

What is Psyence Biomedical Ltd (PBM)'s earnings per share (EPS) for the last quarter?

Psyence Biomedical Ltd. EPS for the last quarter amounts to -251456.00 USD, decreased

How many employees does Psyence Biomedical Ltd (PBM). have?

Psyence Biomedical Ltd (PBM) has 12 emplpoyees as of May 10 2026.

What is Psyence Biomedical Ltd (PBM) market cap?

Today PBM has the market capitalization of 6.41M USD.